Atrion (NASDAQ:ATRI) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Atrion (NASDAQ:ATRI – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the medical instruments supplier’s stock.

Atrion Price Performance

Shares of ATRI stock opened at $607.00 on Thursday. Atrion has a 1-year low of $534.99 and a 1-year high of $766.72. The stock’s 50-day moving average is $645.05 and its 200 day moving average is $614.61. The company has a market cap of $1.07 billion, a P/E ratio of 31.05 and a beta of 0.44.

Institutional Investors Weigh In On Atrion

A number of institutional investors have recently added to or reduced their stakes in the stock. Raymond James & Associates boosted its holdings in Atrion by 686.5% in the third quarter. Raymond James & Associates now owns 7,165 shares of the medical instruments supplier’s stock worth $4,048,000 after acquiring an additional 6,254 shares in the last quarter. First Trust Advisors LP acquired a new stake in Atrion in the fourth quarter worth about $1,598,000. M&T Bank Corp acquired a new stake in Atrion in the fourth quarter worth about $1,199,000. ProShare Advisors LLC boosted its holdings in Atrion by 14.1% in the fourth quarter. ProShare Advisors LLC now owns 14,904 shares of the medical instruments supplier’s stock worth $8,338,000 after acquiring an additional 1,842 shares in the last quarter. Finally, Aviva PLC acquired a new stake in Atrion in the fourth quarter worth about $953,000. Institutional investors own 64.90% of the company’s stock.

About Atrion

(Get Rating)

Atrion Corp. engages in the manufacture and development of products for medical applications. It offers products for cardiovascular, fluid delivery, and ophthalmic. It also offers contract manufacturing and kitting services, and marine & aviation inflation components. The company was founded in 1944 and is headquartered in Allen, TX.